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CASE REPORT
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Neuromyelitis optica (NMO or Devic’s syndrome) is a rare autoimmune disease, previously
considered a multiple sclerosis variant. The most important laboratory and clinical features
are optic myelitis and transverse myelitis, associated with neuromyelitis optica-IgG antibody
(NMO-IgG) positivity. Subsequent to this immunological test being available, different
groups have described the not-so-rare comorbidity of neuromyelitis optica with other systemic
autoimmune diseases, systemic lupus erythematosus with secondary anti-phospholipid syn-
drome (APS) in particular. We describe a patient meeting both the classification criteria for
primary APS and the new diagnostic criteria for neuromyelitis optica. It’s important to diag-
nose NMO syndrome as both optic neuritis and transverse myelitis were also considered
neurological complications of antiphospholipid syndrome. NMO-IgG is a new and fundamen-
tal test to decide if immunosuppressant therapy is warranted for such patients. Lupus (2010)
0, 1–3.
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Case presentation
A 50-year-old white man was admitted to the hos-
pital because of sudden loss of sensation and weak-
ness of the lower limbs. His past medical history
was remarkable for deep vein thrombosis when he
was 20 years old and ischemic stroke in the left
hemisphere, with residual right hemiparesis, when
he was 45 years old. Lupus anticoagulant, anticar-
diolipin and anti-B2GPI antibodies were persis-
tently highly positive. As anti-nuclear (ANA),
extractable nuclear antigen (ENA) and anti-DNA
antibodies were not detected and as he had no
symptoms of connective tissue diseases, primary
antiphospholipid syndrome (APS) was diagnosed,
at which time warfarin therapy was started with an
international normalized ratio (INR) target of 2.5–
3.5. One year later he developed left optic neuritis,
with no radiological or cerebro-spinal fluid findings
suggestive of multiple sclerosis. High dose
glucocorticoids were administered with gradual
recovery of visual acuity.
He was well until the age of 50, after which he
complained of sudden abdominal numbness, under
the D10–D12 level, which progressively extended to
the lower limbs. After a few hours he was unable to
stand or walk. On arrival at the hospital he had
bilateral leg weakness (Medical Research Council
scale 2/5 left leg and 3/5 right leg). Babinsky sign
was bilaterally positive. He subsequently developed
bowel and urinary retention, which required laxative
therapy and a bladder catheter insertion. No new
visual deficit was reported. Magnetic resonance
imaging (MRI) showed T2 hyperintense signal
with swelling involving the spinal cord from T6 to
L1 level (Figure 1). A transverse myelitis was diag-
nosed and the patients was treated with high dose
intravenous methylprednisolone (1 gr/die for 7
days), with gradual although incomplete recovery of
neurological symptoms. A second MRI, performed
10 days after corticosteroideal therapy, showed a sig-
nificant reduction of the spinal inflammation to
T8–T11 segments (Figure 2). As he was diagnosed
as having an APS-associated transverse myelitis, war-
farin therapy was titrated to target an INR of 3.0–4.0.
Subsequent to discharge from the hospital, he was
regularly followed at our center. After a thorough
review of hismedical history, considering the previous
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optic neuritis episode associated with the recent
transverse myelitis attack, we decided to test the
patient’s serum for NMO-IgG antibody. After the
latter positive result, neuromyelitis-optica associated
to primary APS was diagnosed and azathioprine
(2mg/kg/day) was started.
Discussion
Neuromyelitis optica (NMO or Devic’s syndrome)
is a rare autoimmune disease, previously considered
a variant of multiple sclerosis, which differs from
pathogenesis and more aggressive clinical course.1
New criteria, recently developed to correctly diag-
nosis the disease, include: neurological findings
(optic neuritis and transverse myelitis), MRI pat-
tern (lesions distribution not meeting multiple scle-
rosis criteria and longitudinal extensive transverse
myelitis (LETM) involving more than three contig-
uous vertebra) and, most importantly, serological
positivity for neuromyelitis optica-IgG antibody
(NMO-IgG).2 As T2 images show spinal cord
edema and T1 images with gadolinium contrast
well document blood-spinal cord barrier damage,
MRI is the preferred imaging technique to detect
transverse myelitis. Soon after the NMO-IgG test
was available, different authors have described the
association between neuromyelitis optica and other
autoimmune diseases, systemic lupus erythemato-
sus with secondary antiphospholipid syndrome in
particular.3–6 NMO-IgG is indeed considered the
most important diagnostic tool. Considering its
high specificity (94%) and sensitivity (76%), it
was initially developed to differentiate neuromyeli-
tis optica from multiple sclerosis.7 Transverse mye-
litis or optical neuritis can occur simultaneously or
more often at different times, as shown by our
patient who developed myelitis four years after
the previous optic neuritis attack.
Knowledge of the disease is hence required in a
rheumatological setting, as optic neuritis and trans-
verse myelitis have been linked to the wide spectrum
of APS-central nervous system (CNS) involvement
creating differential diagnosis problems if NMO-Ig
is not tested.8–9 To our knowledge this is the first
case of neuromyelitis associated with a confirmed
isolated primary APS. Until recently antiphospholi-
pid syndrome was reported to be associated with
both optic neuritis and transverse myelitis, but we
cannot rule out that for some of these cases the diag-
nosis of NMOwasmissed, as theNMO-IgG test was
not available in the past. However NMO-Ig positiv-
ity remains strongly associated with antiphospholi-
pid antibodies and to explain this phenomena we
Figure 1 Pre-therapy MRI findings: sagittal acquisitions on
spinal cord, T2-weighted (left) and T1-weighted with
Gadolinium contrast medium (right) images. On the T2-
weighted image, a long (from T6 to L1 level) intramedullary
hyperintense area (white arrows), due to edema, is well visible.
The same hyperintense finding on the enhanced T1-weighted
image (white arrows) is attributable to the interruption of
blood-brain barrier due to inflammation.
Figure 2 Post 1 week therapy MRI findings: sagittal acquisi-
tions on spinal cord T2-weighted (left) and T1-weighted with
Gadolinium contrast medium (right) images. Significant
decrease of the pre-therapy findings on both T2- and T1-
weighted images (white arrows), due to diminished inflamma-
tory edema and to blood-brain barrier restoration.
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propose a two hit model, in which the APS antibo-
dies determine endothelial dysfunction and blood
barrier damage (first hit), therefore permitting
NMO-IgG to pass into the CNS and to start inflam-
mation in target tissue (second hit).10 If we start to
consider NMO as a new distinct but possibly asso-
ciated autoimmune disease, in the future it will be
necessary to differentiate APS patients who need
titration of anticoagulant therapy from patients
who need to start immunosuppressive drugs (azathi-
oprine, plasmapheresis or rituximab for the most
resistant cases) such as the patient we describe in
this case report.
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